ARDS News and Press, Aridis Pharmaceuticals Inc. From 11/30/22

A California-based %Biotech company turned heads on Wednesday after the company announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase 2a clinical trial of AR-501 in %CysticFibrosis (CF) patients. According to the release, th...

Los Gatos, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced the closing of patient enro...

The C ompany’s superiority Phase 3 ‘ASAP-1' study of AR-301 monoclonal antibody in S. aureus pneumonia and the pending data readout will be a focus of the KOL event Los Gatos, Calif., Nov. 22, 2022 (GLOBE NEWS...

Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year LOS GATOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the disco...

·         BARDA prioritizing the development of host-targeting and pathogen-agnostic therapeutics for treatment of hospitalized COVID-19 and other serious diseases of the lung Wakefield, MA - ( NewMediaWire ) - November 15, 2022 - Innovation P...

Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study PR Newswire On track to complete data compilation and analyses, with top-line data expected to be announced in December '22 LOS GATOS, Calif. , O...

Aridis Pharmaceuticals ( NASDAQ: ARDS ) withdraws its proposed public offering of shares of its common stock due to to adverse market conditions. "Due to the current market environment and in the interest of achieving the best value for our stockholders, we have decided ...

Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock PR Newswire LOS GATOS, Calif. , Sept. 27, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development...

Aridis Pharmaceuticals ( NASDAQ: ARDS ) on Monday announced a proposed public stock offering. Shares of the micro-cap biopharma were 29.7% lower at $0.85 in afternoon trading. The company said it intends to use the net proceeds from the offering for clinical develo...

Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire LOS GATOS, Calif. , Sept. 26, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of n...